Dexcom (DXCM) Receives Consensus Rating of “Buy” from Analysts

Shares of Dexcom (NASDAQ:DXCM) have earned a consensus recommendation of “Buy” from the twenty-five brokerages that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $71.06.

Several equities research analysts recently commented on the stock. TheStreet raised shares of Dexcom from a “d” rating to a “c-” rating in a research report on Thursday, May 10th. Bank of America assumed coverage on shares of Dexcom in a research report on Friday, May 11th. They issued a “buy” rating and a $100.00 price objective on the stock. Morgan Stanley boosted their price objective on shares of Dexcom from $56.00 to $70.00 and gave the company an “equal weight” rating in a research report on Friday, May 4th. ValuEngine raised shares of Dexcom from a “hold” rating to a “buy” rating in a research report on Thursday, May 3rd. Finally, Canaccord Genuity boosted their price objective on shares of Dexcom from $81.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 3rd.

Shares of NASDAQ DXCM opened at $86.65 on Friday. Dexcom has a twelve month low of $42.62 and a twelve month high of $88.60. The company has a debt-to-equity ratio of 0.79, a current ratio of 5.83 and a quick ratio of 5.42.



Dexcom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, May 2nd. The medical device company reported ($0.32) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.32). The company had revenue of $184.40 million for the quarter, compared to analysts’ expectations of $172.66 million. Dexcom had a negative net margin of 4.30% and a negative return on equity of 9.32%. The business’s quarterly revenue was up 29.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.49) earnings per share. equities analysts expect that Dexcom will post -0.52 earnings per share for the current fiscal year.

In other Dexcom news, SVP Jacob Steven Leach sold 1,923 shares of the business’s stock in a transaction dated Tuesday, May 8th. The shares were sold at an average price of $84.95, for a total transaction of $163,358.85. Following the sale, the senior vice president now directly owns 100,801 shares of the company’s stock, valued at approximately $8,563,044.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard Doubleday sold 1,638 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $56.32, for a total transaction of $92,252.16. Following the sale, the executive vice president now directly owns 65,049 shares in the company, valued at $3,663,559.68. The disclosure for this sale can be found here. Insiders have sold a total of 117,432 shares of company stock worth $9,638,262 over the last three months. Insiders own 1.80% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Xact Kapitalforvaltning AB lifted its position in Dexcom by 50.6% during the 1st quarter. Xact Kapitalforvaltning AB now owns 12,200 shares of the medical device company’s stock worth $905,000 after buying an additional 4,100 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Dexcom by 11.4% during the 1st quarter. Royal Bank of Canada now owns 135,724 shares of the medical device company’s stock worth $10,065,000 after purchasing an additional 13,850 shares during the last quarter. Integre Asset Management LLC increased its stake in shares of Dexcom by 900.0% during the 1st quarter. Integre Asset Management LLC now owns 44,229 shares of the medical device company’s stock worth $3,280,000 after purchasing an additional 39,806 shares during the last quarter. Iguana Healthcare Management LLC acquired a new position in shares of Dexcom during the 1st quarter worth about $2,596,000. Finally, Point72 Asset Management L.P. increased its stake in shares of Dexcom by 429.3% during the 1st quarter. Point72 Asset Management L.P. now owns 979,175 shares of the medical device company’s stock worth $72,616,000 after purchasing an additional 794,175 shares during the last quarter.

About Dexcom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Analyst Recommendations for Dexcom (NASDAQ:DXCM)

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply